Posts by Chung Yin Kong, PhD
-
Improving Cost-effectiveness of Second-line Pembrolizumab for Advanced Urothelial Carcinoma
Among patients with advanced urothelial carcinoma who need second-line therapy, reserving pembrolizumab for those whose tumors express PD-L1 may improve cost-effectiveness, according to computer modeling studies at Massachusetts General Hospital.
Biography
Dr. Kong is committed to pursuing an academic research career to study and improve health policy making. He has both academic and industrial experience working on computer modeling of various fields including macromolecules, protein binding, traffic routing, signal processing, and disease simulation modeling. His current research interests are on using modeling to investigate the benefits and harms of lung cancer screening and the applications of advanced engineering simulation methods on cancer screening simulations.
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.